The U.S. District Court for the District of Delaware upheld Amgen’s patent on the cholesterol drug Repatha, rejecting the challenge by Sanofi and Regeneron.

Repatha, a monoclonal antibody designed to inhibit PCSK9 from binding to the low-density lipoprotein (LDL) receptor (LDLR), holds approval in more than 60 countries, including the US, Japan, Canada and multiple European Union members.

Sanofi and Regeneron admitted to infringement of Amgen’s patents in 2016. The previous jury partially reversed their decision on appeal, which sent the case to the district court. Sanofi and Regeneron make a similar drug called Praluent that prevents PCSK9 binding to LDLR.

Sanofi and Regeneron said they intend to file post-trial motions to overturn the verdict and request a new trial.

Subscribe To Our Newsletter

Would you like to receive our popular weekly news alerts straight to your inbox? Solely patent focused and only sent once a week means you can guarantee there will be something you are interested in reading instead of clogging up your inbox with junk. Sign up now!

You have Successfully Subscribed!